A share price of EyePoint Pharmaceuticals Inc [EYPT] is currently trading at $22.45, down -1.92%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EYPT shares have gain 10.70% over the last week, with a monthly amount glided 1.63%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] stock has seen the most recent analyst activity on January 22, 2024, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $35. Previously, Mizuho started tracking the stock with Buy rating on November 02, 2023, and set its price target to $20. On April 21, 2023, Robert W. Baird initiated with a Outperform rating and assigned a price target of $33 on the stock. Chardan Capital Markets started tracking the stock assigning a Buy rating and suggested a price target of $21 on July 07, 2022. Cowen initiated its recommendation with a Outperform and recommended $25 as its price target on March 01, 2021. Cantor Fitzgerald started tracking with a Overweight rating for this stock on January 28, 2021, and assigned it a price target of $22. In a note dated April 06, 2020, B. Riley FBR downgraded an Neutral rating on this stock and revised its target price from $4 to $1.
EyePoint Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $3.32 and $30.99. Currently, Wall Street analysts expect the stock to reach $25 within the next 12 months. EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] shares were valued at $22.45 at the most recent close of the market. An investor can expect a potential return of 11.36% based on the average EYPT price forecast.
Analyzing the EYPT fundamentals
Trailing Twelve Months sales for EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] were 46.02M which represents 33.18% growth. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.63%, Pretax Profit Margin comes in at -1.54%, and Net Profit Margin reading is -1.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.62 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.80 points at the first support level, and at 21.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.37, and for the 2nd resistance point, it is at 24.30.
Ratios To Look Out For
To put it in perspective, the Current Ratio for EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] is 5.45. As well, the Quick Ratio is 5.39, while the Cash Ratio is 4.45. Considering the valuation of this stock, the price to sales ratio is 24.31, the price to book ratio is 4.13.
Transactions by insiders
Recent insider trading involved Jones David Scott, SVP & Chief Commercial Officer, that happened on Feb 02 ’24 when 209.0 shares were sold. Chief Medical Officer, Paggiarino Dario A. completed a deal on Jan 26 ’24 to sell 49325.0 shares. Meanwhile, SVP & Chief Commercial Officer Jones David Scott sold 26017.0 shares on Jan 26 ’24.
